Medexus Pharmaceuticals (MDP.TO), a leading specialty pharma company, today announced that it has secured the Canadian rights to commercialize terbinafine hydrochloride nail lacquer supplied by Polichem, an Almirall group…
Pharmaceuticals
Specialty pharmaceuticals is a unique niche in the pharma sector. Where companies like Eli Lilly pour billions into developing a drug candidate from scratch with the very real possibility…
Specialty pharma company, Medexus Pharmaceuticals (MDP.TO) released fiscal Q3 2023 (quarter ended December 31st 2022) operating and financial results. The company has announced another record quarter with revenue of…
Medexus Pharmaceuticals (MDP.TO) today announced that it has reached an agreement with the provincial government of Quebec for government sponsored coverage of Cuvposa. The glycopyrrolate oral solution will be…
*originally published 01-16-23 Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company. They are not biotech. There is no research and development here. Medexus is all about sales and marketing, bringing…
Medexus Pharmaceuticals (MDP.TO) today announced preliminary estimates of the company’s revenue results for the quarter ended December 31st 2022 (fiscal Q3 2023). After Q2 2023 being Medexus’ strongest quarter…
Specialty pharma company Medexus Pharmaceuticals (MDP.TO) announced today that it plans to host a conference call at 8:00 am EST on Wednesday November 9th 2022. The call will discuss…
Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company that has been making big moves on the charts. The company is not a biotech company. They do not do research…
Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company. They are not biotech. There is no research and development here. Medexus is all about sales and marketing, bringing over drugs…
Specialty pharma company Medexus Pharmaceuticals (MDP.TO) provided an update on the Treosulfan NDA resubmission and provided a business update. On September 16th 2022, Medexus was informed by Medac, licensor…